These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32642685)

  • 1. Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim-Chester disease patients following BRAF inhibitor monotherapy.
    Mazor RD; Weissman R; Luckman J; Domachevsky L; Diamond EL; Abdel-Wahab O; Shapira S; Hershkovitz-Rokah O; Groshar D; Shpilberg O
    Neurooncol Adv; 2020; 2(1):vdaa024. PubMed ID: 32642685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
    Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
    JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
    Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
    J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: Targeted treatment strategies for Erdheim-Chester disease.
    Gulyás A; Pinczés LI; Mátyus J; Végh E; Bedekovics J; Tóth J; Barna S; Hunya Z; Szabó IL; Gazdag A; Illés Á; Magyari F
    Front Oncol; 2024; 14():1305518. PubMed ID: 38549927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].
    Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-World Toxicity Experience with BRAF/MEK Inhibitors in Patients with Erdheim-Chester Disease.
    Saunders IM; Goodman AM; Kurzrock R
    Oncologist; 2020 Feb; 25(2):e386-e390. PubMed ID: 32043767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic Efficacy of Interferon and Vemurafenib on Psychiatric Symptoms Revealing
    Razanamahery J; Abdallahoui M; Chabridon G; Fromont A; Tarris G; Idbaih A; Comby PO; Godard F; Haroche J; Audia S; Bonnotte B
    Front Immunol; 2022; 13():918613. PubMed ID: 35874752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
    Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
    Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
    Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
    Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the
    Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R
    Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erdheim-Chester Disease With BRAF V600E Mutation and Central Diabetes Insipidus Successfully Treated With Glucocorticoid.
    Imaizumi T; Daido H; Kato T; Yabe D
    JCEM Case Rep; 2023 Mar; 1(2):luad014. PubMed ID: 37908458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib as first-line therapy in
    Fernández-Eulate G; Muñoz-Lopetegi A; Ruiz I; Urtasun M
    BMJ Case Rep; 2019 Nov; 12(11):. PubMed ID: 31748352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoalphalipoproteinemia and BRAF
    Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease.
    Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J
    Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Young JR; Johnson GB; Murphy RC; Go RS; Broski SM
    J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
    Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
    Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
    Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
    Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF
    Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA
    Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system involvement in Erdheim-Chester disease: a magnetic resonance imaging study.
    Zahergivar A; Firouzabadi FD; Homayounieh F; Golagha M; Huda F; Biassou N; Shah R; Nikpanah M; Mirmomen M; Farhadi F; Dave RH; Shekhar S; Gahl WA; Estrada-Veras JI; Malayeri AA; O'Brien K
    Clin Imaging; 2024 Nov; 115():110281. PubMed ID: 39270429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erdheim-Chester Disease: The Importance of Information Integration.
    Nikonova A; Esfahani K; Chausse G; Probst S; Petrogiannis-Haliotis T; Knecht H; Gyger G
    Case Rep Oncol; 2017; 10(2):613-619. PubMed ID: 28868020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.